Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II
被引:40
作者:
Feng, Yangbo
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Feng, Yangbo
Cameron, Michael D.
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Cameron, Michael D.
Frackowiak, Bozena
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Frackowiak, Bozena
Griffin, Evelyn
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Griffin, Evelyn
Lin, Li
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Lin, Li
Ruiz, Claudia
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Ruiz, Claudia
Schroter, Thomas
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
Schroter, Thomas
LoGrasso, Philip
论文数: 0引用数: 0
h-index: 0
机构:Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
LoGrasso, Philip
机构:
[1] Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA
[2] Scripps Res Inst, Dept Drug Discovery, Jupiter, FL 33458 USA
ROCK has been implicated in many diseases ranging from glaucoma to spinal cord injury and is therefore all important target for therapeutic intervention. In this study, we have designed a series of 1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-hydroxy(or 2-amino) analogs and a series of 1-(4-(1H-indazol-5-yl amino)piperidin-1-yl)-2-hydroxy(or 2-amino) inhibitors of ROCK-II. SR-1459 has IC50 = 13 nM versus ROCK-II while the IC(50)s for SR-715 and SR-899 are 80 nM and 100 nM, respectively. Many of these inhibitors, especially the 2-amino substituted analogs for both series, are modest/potent CYP3A4 inhibitors as well. However, a few of these inhibitors (SR-715 and SR-899) show strong selectivity for ROCK-II over CYP3A4, but the overall potency of the 2-amino analogs (SR-1459) on CYP3A4 and the high clearance and volume of distribution of these compounds makes the in vivo utility of these analogs undesirable. (c) 2007 Elsevier Ltd. All rights reserved.
机构:
GlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USAGlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USA
Hu, E
;
Lee, D
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USAGlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USA
机构:
GlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USAGlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USA
Hu, E
;
Lee, D
论文数: 0引用数: 0
h-index: 0
机构:
GlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USAGlaxoSmithKline, Dept Vasc Biol, Ctr Excellence Cardiovasc & Urogenital Drug Disco, King Of Prussia, PA 19406 USA